Introduction
Worldwide lung cancer is the leading cause of cancer death with 1.6 million deaths annually, exceeding those from any other malignancy [1] . Lung cancer is the most common cause of cancer death in men and the second leading cause of cancer death in women, worldwide. It is the commonest cancer in Asia and is the leading cause of death in Southern, Eastern and South Eastern Asia [2] . Fifty-one percent of the world's lung cancer cases occur in Asia [3] , and 21% of cancer deaths in Asia are due to lung cancer [4] . The number of cases and the crude and standardised incidence rates (both sexes) for lung cancer in 5 Asian countries per 100 000 people in the population were as follows: for China 774 323, 47.8 and 22.8 [5] ; for South Korea 22 873, 47.1 and 28.7; for Singapore 1974, 37.6 and 24.9; for Japan 94 855, 75.0 and 24.6 and for Malaysia 4403, 15.0 and 17.9 [2] . Globally cigarette smoking alone is responsible for over 80% of cases of lung cancer [6] . China is currently the largest consumer of tobacco in the world with 301 million smokers [7] . Approximately two-thirds of young Chinese men smoke, and estimates indicate that half of them will die as a result of smoking if they do not quit [8] . It is estimated that deaths from smoking in China will have reached around 2 million annually by 2030 and 3 million annually by 2050 [4, 9] . Lung cancer is responsible for the highest number of cancer deaths in Korea [10] , and is the leading cause of cancer death in men in Japan [11] . In both countries, the rate of smoking has declined although in Korea the prevalence of lung cancer is expected to continue to rise for the next 20-30 years. In Japan, there is also the 'the Japanese Lung Cancer Smoking Paradox', where although the prevalence of cigarette smoking amongst Japanese men has been consistently higher than amongst their Western counterparts, the incidence of and mortality rates for lung cancer in Japan have been consistently lower than those for Western countries [12] [13] [14] .
Interest is also increasing in understanding the aetiology of lung cancer in non-smokers [15, 16] . Worldwide, 500 000 deaths annually are attributed to lung cancer in individuals who have never smoked [4] , with the increase in the proportion of non-small-cell lung cancer (NSCLC) in individuals who have never smoked being especially marked in Asian countries [17] . A recent Korean study of 5456 cases of lung cancer in a community cancer centre showed the proportion of cases in never smokers to have increased from 19 .4% between 2004 and 2008 to 25.4% between 2009 and 2012 [18] .
Epidemiological data have resulted in 'non-smoking-associated lung cancer' being considered a distinct disease entity, where specific molecular and genetic differences have been identified between the lung cancers of smokers compared with those of never smokers [19] . Data from the analysis of six, large, Western population-based cohorts, showed the differences between the lung cancers in those individuals who had never smoked and those who were long-term smokers to be apparent in their differential responses to epidermal growth factor receptor (EGFR) inhibitors and in the increased prevalence of adenocarcinomas in never smokers [16] . These data also supported the observation that women are more likely than men to have non-smokingassociated lung cancer, and were consistent with the data for Asian women with lung cancer who never smoked [20] .
There are no comprehensive guidelines for the treatment of metastatic NSCLC (mNSCLC) in Asia, although Japan [21] has its own lung cancer treatment guidelines and China has the Chinese Society of Clinical Oncology (CSCO) Lung Cancer Practice guidelines stratified by resource availability and treatment values [22] . A decision was taken by CSCO, the Chinese Thoracic Oncology Group (CTONG) and European Society of Medical oncology (ESMO) to develop guidelines adapted from the most recent 2016 and 2018 versions of the ESMO Clinical Practice Guidelines for the treatment and management of Asian patients with mNSCLC [23, 24] . A 1-day working meeting was held on the 5 August 2018 in Guangzhou, China, for this purpose.
Methodology
This Pan-Asian adaptation of the ESMO guidelines was prepared in accordance with the processes and format developed for the preparation of the first Pan-Asian adapted ESMO guidelines for the management of patients with metastatic colorectal cancer [25] .
Composition of expert panel
The international panel of experts was selected according to their demonstrable knowledge of the field of NSCLC patient treatment and management in terms of publications and/or their participation in the development of national or international treatment guidelines. More specifically this included two expert members of the CSCO, two expert members from the ESMO and two experts each from the oncological societies of Japan (JSMO), Korea, (KMSO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). Only Asian expert members were allowed to vote on the recommendations.
Provisional statements
A set of preformulated topics and 24 recommendations for the treatment of mNSCLC, from those in the latest ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of mNSCLC [23] , were circulated, before the meeting, to each of the 12 Asian experts representing the six Asian oncological societies to gather their comments and input on each of the recommendations with specific emphasis being placed on the current practice in their countries and the data available from studies in Asian patients. The Asian experts were specifically asked 'Is this recommendation adaptable for use in your country?' The 12 experts were also asked to provide details of the reasoning behind their responses and the relevant references to support their decisions. In the case of the present guidelines, a second survey was circulated shortly before the face-to-face meeting to ask the opinion of the experts on the updates to the recent ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up submitted to Annals of Oncology July 2018 [24] .
Voting process
A modified Delphi process was used to develop each individual statement before the final discussion and final voting process at the face-to-face working meeting in Guangzhou. The 12 Asian experts were asked to vote based on the evidence available, on a scale of A to E, where A ¼ accept completely; B ¼ accept with some reservation; C ¼ accept with major reservation; D ¼ reject with some reservation and E ¼ reject completely (Table 1 ). An adapted version of the 'Infectious Diseases Society of AmericaUnited States Public Health Service Grading System' [26] was used to define the level of evidence and strength (grade) of each recommendation proposed by the group, as for all of the ESMO Consensus and ESMO Clinical Practice Guidelines (Table 1) and are given in the text in square brackets after each recommendation together with details of the levels of agreement. Most statements on the level of agreement were based on peer-reviewed manuscript data or peer-reviewed abstract data, although statements made based on expert opinion were also considered to be justified standard clinical practice by the experts and the CSCO and ESMO faculty. Whenever possible, the score of the ESMO Magnitude of Clinical Benefit Scale (MCBS) was provided for the most recently approved drugs (all MCBS scores are available in Open Access at https://www.esmo.org/score/cards). The Asian experts were asked to make their decisions based on the available 'scientific evidence' rather than on some of the current practices in their respective countries, and also, independently of the approval and reimbursement status of certain drugs in their individual countries. The two experts, from ESMO (JYD and DP) were present at the face-to-face meeting in Guangzhou, China to offer their expert opinion if and as required.
Final consensus statements
A consensus was considered to have been achieved when 80% of experts voted to accept completely or accept with reservation a specific recommendation. A recommendation was considered to have been rejected when >80% of the voting members indicated 'reject completely' or 'reject with reservation'. For recommendations where a consensus was not reached initially the panel of Asian experts was invited to discuss and modify the recommendation(s) at the face-to-face meeting and a second round of voting was conducted. If still no consensus could be reached, the recommendation could be modified one more time, and a third and last vote was conducted to determine the definitive acceptance or rejection of a recommendation.
Results
Before the face-to-face meeting, the 12 experts representing the oncological societies of the 6 Asian countries and associated regions (China, Japan, Korea, Malaysia, Singapore and Taiwan) reported on the applicability of 137 recommendations from the 2016 ESMO NSCLC Clinical Practice Guidelines [23] and subsequently the updated ESMO 2018 Clinical Practice Guidelines for the diagnosis treatment and follow-up of mNSCLC [24] . These were in the 24 categories: and for the purposes of the evaluation and voting process were numbered recommendations 1-24 with the subcategories assigned a letter code (a, b, c etc.). An unqualified response of YES in the pre-meeting surveys equated with 'accept completely' in the final voting, i.e. A ¼ 100%. Following the pre-meeting surveys agreement was not reached between the six Asian countries on recommendations 2f and g, 3c, e, f, g and l, 5c and n, 6d, 7d, 9d, e, j and k, 10d, 11e and g, 13d and f, 18a and i, 19c and 20e (supplementary Table S1 -S12, available at Annals of Oncology online). At the face-to-face meeting in Guangzhou, the nine Asian experts in the treatment of NSCLC present (two Japanese experts and one Malaysian expert were unable to attend) were asked to Table S13 , available at Annals of Oncology online.
Where changes to the original text have been made, including the addition of new subcategories and in some cases the revision of an existing recommendation, these are emphasised in bold both in the main text of the manuscript and in Table 2 , and reference made to the change in the text as appropriate. In parallel, the final voting patterns of the representatives of each of the participating regions for the ESMO recommendations at the face-to-face meeting in Guangzhou are presented in supplementary Table S13 , available at Annals of Oncology online. All 12 Asian experts agreed with and accepted completely [A ¼ 100%] 'recommendations 1a-f' above taken from the ESMO 2018 guidelines for mNSCLC [24] . The evidence from Western studies shows that multidisciplinary teams improve the management and clinical outcomes of patients with NSCLC [27] [28] [29] [30] . Most patients with suspected lung cancer require a tissuebased diagnosis often involving challenging tissue sampling. Tissue sampling provides for the confirmation of the initial diagnosis [e.g. non-squamous cell carcinoma (NSCC) versus squamous cell carcinoma (SCC)], facilitates molecular testing and informs the individual patient treatment decisions and care.
As described previously [24] , bronchoscopy is ideally suited to large, central lesions and can be used for bronchial washing, brushing, and transbronchial needle biopsy with the advantage of minimal morbidity [31] [32] [33] . Bronchoscopic airway visualisation combined with ultrasound, EBUS, can also be used to biopsy large, centrally located lesions [34, 35] , diagnose and stage lung cancer, and to determine if the disease has spread to e.g. the lymph nodes. EBUS-guided transbronchial needle aspiration (TBNA) is reported to be at least as accurate as mediastinoscopy but less invasive [36] . Cytological specimens obtained by EBUS-TBNA have been shown to be suitable for molecular testing [37] [38] [39] [40] . For peripheral lesions, transthoracic percutaneous fine needle aspiration and/or core biopsy, under imaging guidance (typically computed tomography [CT] ) is proposed/recommended [41] , and is associated with high diagnostic accuracy [32, [42] [43] [44] [45] , although there is a risk of pneumothorax [44, 45] . In cases of pleural effusion, thoracentesis can be used for both diagnosis and palliative treatment. If the fluid cytology results are negative, an image-guided pleural biopsy or surgical thoracoscopy should be carried out. Where the techniques described above are unable to provide an accurate diagnosis more invasive, surgical approaches should be considered. Tables 3 and 4. 3i. In the presence of a solitary metastatic site on imaging studies, efforts should be made to obtain a cytological or histological confirmation of stage IV disease [A¼100% and IV, A]. 3j. Response evaluation is recommended after 6-9 weeks of systemic therapy using the same radiographic investigation that initially demonstrated tumour lesions [A¼100% and IV, B]. 3k. Follow-up with PET is not routinely recommended, due to its high sensitivity and relatively low specificity [A¼100% and IV, C]. 3l. Measurements and response assessment should follow RECIST criteria v1.1 [B¼100% and IV, A]. However, the adequacy of RECIST in evaluating the response to targeted therapy like EGFR or ALK TKI in respective genetically-driven NSCLC is debatable [B¼100% and IV, B]. 3m. In the case of immune checkpoint inhibitor therapy, RECIST criteria should be used, although irRECIST, iRECIST, imRECIST may have a role in the overall assessment of therapy [A¼100% and IV, B]. Recommendation 5: first-line treatment of NSCLC without a druggable oncogene driver 5a. Chemotherapy should be considered for all stage IV NSCLC patients with EGFR-and ALK-negative disease, in the case of a contraindication to immunotherapy, and who are without major comorbidities and PS 0-2 [A¼100% and I, A]. 5b. Single agent pembrolizumab should be considered in eligible patients with PS 0-1, EGFR-and ALK-negative NSCLC and a tumour with a TPS of PD-L1 50% [A¼100% and I, A]. Chemotherapy should be provided in the case of contraindication to pembrolizumab. 5c. Pembrolizumab plus chemotherapy (with pemetrexed plus platinum) should be considered in patients with PS 0-1, non-squamous NSCLC without EGFR or ALK mutations, in absence of contraindications to the use of immunotherapy, if approved and available [A¼17%, B¼83% and I, A] ( Figure 2 ). The survival benefit for pembrolizumab-combination therapy is observed across all categories of PD-L1 expression, but diminished among PD-L1-negative patients and it is unclear if chemotherapy adds a benefit in patients with PD-L1 50%. supplementary Table  S1 , available at Annals of Oncology online) were not in agreement, one country because FISH was not used for screening in their country (recommendation 2f) and the other because testing is not reimbursed in their country (it is only done if the drug company pays for the test) 'recommendation 2g'. After discussion at the face-to-face meeting, all countries accepted completely [A ¼ 100%] 'recommendations 2a-k' based on the available scientific evidence rather than the situation in their countries. A minor revision was made to the wording of 'recommendation 2g' to include the addition of the words 'a validated reverse transcription polymerase chain reaction (RT-PCR) test may be used as an alternative' (see also in bold text above), because in Asia the technique is standard. Minor revisions were also made to 'recommendation 2k' for clarity (see bold text above). The histological diagnosis of NSCLC from both surgically resected tumours and small biopsies should be based on the WHO classification published in 2015 [46, 47] .
Therapeutic decisions are based on the specific histological subtype of the tumour. Sampling may be carried out on the primary tumour or any accessible metastases either surgically or using image-guided techniques. Immunohistochemistry (IHC) should be used, particularly in the small sample setting, where specific subtyping is not possible by morphology alone, and to reduce the number of patients classified as having NSCLC-NOS (not otherwise specified) to <10% of diagnosed cases [1V, A] [46] . IHC should be restricted to the use of thyroid transcription factor 1 (TTF1) to predict a probable diagnosis of adenocarcinoma, and p40 to predict a probable diagnosis of SCC. If neither are positive the diagnosis is NSCLC-NOS [46, 48] .
IHC is also used for predictive biomarker assessment. Typically testing involves the detection of either targetable, usually addictive oncogenic changes, or biomarker testing for immunooncology therapy [49, 50] . The majority of oncogene-addicted lung cancers are adenocarcinomas and Western and international guidelines suggest that all patients with advanced probable or definitive adenocarcinoma should be tested for oncogenic drivers [49] [50] [51] [52] . Molecular testing is not recommended for patients with SCC except in the case of never-, long-term ex-or light-(<15 packs/year) smokers. Although PD-L1 expression should be determined ahead of any treatment decision for patients with SCC ('recommendation 2k' and Figure 1 ).
In most European countries, genetic testing for EGFR mutations and rearrangements of ALK and ROS1 are considered mandatory, and testing for BRAF V600E mutations is becoming essentially routine [24] . Evolving targets/biomarkers are human EGFR-2 (HER2), MET exon 14 mutations, and fusion genes involving RET and NRK1.
EGFR TKIs are established as effective therapies in patients who have activating and sensitising mutations in exons 18-21 of [54] . A study in multi-ethnic Malaysian patients with NSCLC showed the prevalence of EGFR mutations (36.4%) to be similar [55] . Generally, female sex, adenocarcinoma histology, never-smoking status, and Asian ethnicity are considered the most important factors associated with EGFR mutation positive disease and response to EGFR-TKIs [54, 56] . As stated previously [24] , the most commonly occurring mutations comprise deletions in exon 19 and a substitution mutation (L858R) in exon 21, and testing should cover these mutations [1, A] . The T790M exon 20 mutation is the most frequent cause of resistance to first-and second-generation EGFR TKIs but is rarely found in TKI-untreated patients although patients with T790M germline mutations have been reported [57] . In the case of accessibility to a third-generation EGFR-TKI (e.g. osimertinib) that can overcome T790M-mediated resistance [58] , testing for T790M mutations should be mandatory [1, A] (see the retrospective addition of 'recommendation 2d-1' and Table 2 ). The use of cell-free DNA (cfDNA) to 'rule in' targetable mutations should be used when sufficient tissue cannot be obtained. However, due to the lack of sensitivity of cfDNA blood testing, all patients who test negative for a T790M mutation at relapse will still require a tissue biopsy [59] . Emerging data also show the presence of the ALK protein (positive IHC staining) to be associated with treatment response [I, A] [60] . IHC has been accepted as an alternative to FISH for ALK testing [50] . ALK mutations represent an important mechanism of resistance to ALK TKIs and ALK mutation testing may therefore become routine at relapse as the newer generation ALK TKIs show differential efficacy against the different ALK mutations [61] . The updated molecular testing guidelines for the selection of lung cancer patients for treatment with targeted TKIs also recommend ROS1 testing of all NSCL adenocarcinomas. ROS1 gene fusions are found in 2.4% of Asian patients with lung adenocarcinomas and are associated with young age at diagnosis [62] . In fact, recommendations from the updated molecular testing guidelines [50] include the inclusion of the testing of additional genes (ERBB2, MET, BRAF, KRAS and RET) for laboratories that perform next-generation sequencing panels, with the use of 5% sensitivity assays for EGFR T790M mutations in patients with secondary resistance to EGFR inhibitors; as well as IHC as an alternative to FISH for both ALK diagnosis and ROS1 screening.
Crizotinib, an inhibitor of ALK, ROS1 and MET, is approved in Europe and the United States for use in patients with ROS1-rearranged adenocarcinomas, has recently demonstrated antitumour activity, with no new safety signals, in East-Asian patients with ROS1-positive advanced NSCLC [63] . Approval of the In absence of contraindications and conditioned by the registration and accessibility of anti-PD-L1 combinations with platinum-based chemotherapy, this strategy will be favoured to platinum-based chemotherapy in patients with PS 0-1 and PD-L1 >50%.
antiprogrammed cell death protein 1 (PD-1) agent pembrolizumab as a standard-of-care first-line treatment in selected patients with high programmed death-ligand 1 (PD-L1) expression (score of at least 50%), based on the findings from the KEYNOTE-024 trial [64] , and subsequent confirmation in the KEYNOTE-042 trial [65] , has resulted in PD-L1 IHC being mandatory for all patients with advanced NSCLC in the first-line setting [ Furthermore, EGFR mutation status has been reported to be inversely associated with PD-L1 [71] , with data in Asian studies suggesting that EGFR-TKIs might indirectly enhance antitumour immunity [72] , and that changes in PD-L1 expression are seen in patients with EGFR-mutant NSCLC who acquire resistance to the TKI gefitinib [73] . Patients with EGFR mutations or ALK rearrangements have been shown to exhibit lower PD-L1 and CD8 co-expression levels in the tumour microenvironment, which could be responsible for a poor response to checkpoint inhibitors. PD-L1 and CD8 co-expression in EGFR-mutated or ALK-rearranged lung cancer has been shown to be a biomarker for poor prognosis with shorter overall survival [74] . A recent analysis also suggests that TP53 and KRAS mutation status may be predictive of response to PD-1 blockade in patients with nonsquamous NSCLC [75] .
Measuring tumour mutational burden (TMB) is also being explored, and high TMB (10 mutations per megabase) has been validated prospectively in a unique prospective clinical trial which showed the PFS seen with nivolumab plus ipilimumab to be significantly longer than for chemotherapy irrespective of PD-L1 expression [76] . Studies are ongoing to define a consensus on how TMB should be measured [77] [78] [79] . Recently, data from the POPLAR and OAK trials showed TMB in blood is associated with atezolizumab clinical benefit in patients with NSCLC [80] . Also, preliminary data suggest that blood TMB may be a predictive biomarker for atezolizumab activity in an analysis of 58 biomarker assessable patients in the B-F1RST trial [81] . A prospective trial in the first-line setting, examining the same biomarker, is ongoing [NCT03178552]. Tables 3 and 4. 3i. In the presence of a solitary metastatic site on imaging studies, efforts should be made to obtain a cytological or histological confirmation of stage IV disease [A ¼ 100% and IV, A]. 3j. Response evaluation is recommended after 6-9 weeks of systemic therapy using the same radiographic investigation that initially demonstrated tumour lesions [A ¼ 100% and IV, B]. 3k. Follow-up with PET is not routinely recommended, due to its high sensitivity and relatively low specificity (see supplementary Table S2 , available at Annals of Oncology online). 'Recommendations 3c, e, f, g and l' were discussed at the face-to-face meeting. The issues over 'recommendations 3c, e and f' were resolved immediately with all the experts accepting them completely [A ¼ 100%]. There was concern about the use of the word should in 'recommendations 3e and 3l', as in some Asian countries should is interpreted as must. Thus, should in the case of 'recommendations 3e and 3l' should be interpreted as may, and the same applies for other recommendations in this document where the word should has been used in a recommendation. All experts accepted 'recommendation 3g' completely [A ¼ 100%], following discussion, with the understanding that in some Asian countries MRI is used to confirm metastases. 'Recommendation 3l' was accepted with some reservation [B ¼ 100%] as Response Evaluation Criteria In Solid Tumors (RECIST) are only used in clinical trials.
As part of the diagnostic process, standard tests including routine haematology, renal and hepatic function, and bone biochemistry tests are required, but the routine use of serum markers, Tumour more than 3 cm but not more than 4 cm in greatest dimension T2b
Tumour more than 4 cm but not more than 5 cm in greatest dimension T3 Tumour more than 5 cm but not more than 7 cm in greatest dimension or one that directly invades any of the following: parietal pleura, chest wall (including superior sulcus tumours) phrenic nerve, parietal pericardium; or separate tumour nodule(s) in the same lobe as the primary T4
Tumour more than 7 cm or of any size that invades any of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina; separate tumour nodule(s) in a different ipsilateral lobe to that of the primary Regional lymph nodes (N) 
M1c
Multiple extra thoracic metastasis in a single or multiple organs
Reprinted from [85] with permission from John Wiley & Sons Inc. a Tis includes adenocarcinoma in situ and squamous carcinoma in situ. b The uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. c Solitary adenocarcinoma (not more than 3 cm in greatest dimension), with a predominantly lepidic pattern and not more than 5 mm invasion in greatest dimension in any one focus. d T2 tumours with these features are classified T2a if 4 cm or less, or if size cannot be determined and T2b if >4 cm but not larger than 5 cm. e Most pleural (pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is non-bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumour, the effusion should be excluded as a staging descriptor. f This includes involvement of a single non-regional node.
(P < 0.05) [84] . MRI may complement or improve the diagnostic staging accuracy of 18 F-FDG-PET-CT imaging, particularly in assessing the extent of local chest wall, vascular or skeletal invasion and in the identification of nodal and distant metastatic disease. NSCLC is staged according to the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) system (8th edition) and is grouped into the stage categories shown in Tables 3 and 4 [85, 86] .
As described previously, response evaluation is recommended after two to three cycles of chemotherapy or immunotherapy, using the same initial radiographic investigation techniques used for the original diagnosis [IV, B], and every 6-9 weeks in patients treated with targeted therapies and/or immunotherapy [IV, B] [24] . Lesions should be assessed according RECIST v1.1 [IV, A] [87] . However, it should be noted that evaluating responses to EGFR or ALK TKIs in genetically driven NSCLCs is challenging as treatment beyond RECIST progression is common in these patients in the pursuit of clinical benefit rather than a measurable response. Several radiological criteria have been developed specifically for immunotherapy, namely two-dimensional immunerelated response criteria (irRC) immune-related RECIST (irRECIST) [88, 89] and more recently iRECIST [90] , and immune-modified RECIST (imRECIST) [91] in a bid to standardise the assessment of response for immunotherapy clinical trials. However, non-conventional responses and pseudo progression are very rarely observed in patients being treated for NSCLC, <5% of all cases, and ideally RECIST 1.1 should still be used in routine clinical practice [ All 12 Asian experts agreed with and accepted completely [A ¼ 100%] 'recommendations 4a, b and c' in the pre-meeting surveys. As discussed previously 'recommendation 1', treatment decisions should ideally be discussed within a multidisciplinary team, that is able to evaluate and change patient management, including the recommendation of additional investigations and changes in treatment approach [96] . Smoking cessation should be strongly encouraged as it can improve outcome by improving PS [97] . Also, continued smoking may impact on the efficacy of systemic therapy. For example, smoking is known to reduce the bioavailability of erlotinib [98] . (Figure 2) . The survival benefit for pembrolizumabcombination therapy is observed across all categories of PD-L1 expression, but diminished among PD-L1-negative patients and it is unclear if chemotherapy adds a benefit in patients with PD-L1 50%. 5d. Combination of atezolizumab and bevacizumab with carboplatin and paclitaxel should be considered as a therapeutic option in patients with PS 0-1 and metastatic nonsquamous NSCLC, in the absence of contraindications to b Depending on approval status and reimbursement. ALK, anaplastic lymphoma kinase; BSC, best supportive care; EGFR, epidermal growth factor receptor; Mb, megabase; MCBS, Magnitude of Clinical Benefit Scale; nab-PC, albumin-bound paclitaxel and carboplatin; NSCC, non-squamous cell carcinoma; PD-L1, programmed death-ligand 1; PS, performance status; TMB, tumour mutation burden.
5n Table S13 , available at Annals of Oncology online). Thus, only 'recommendations 5c and n 'were discussed at the face-to-face meeting (see supplementary Table  S3 , available at Annals of Oncology online).
First-line treatment with ICT mAbs in patients with no druggable oncogene driver and no contradictions for the use of immunotherapy. Historically, lung cancers have been considered to be poorly immunogenic, but the emergence of clinical data related to the use of immune checkpoint targeted monoclonal antibodies (ICT mAbs) directed against PD-1, PD-L1 and the cytotoxic T-lymphocyte-associated protein 4 (CTL-4), suggests that immunotherapy has a role to play in the treatment and management of patients with NSCLC. The KEYNOTE-024 trial emphasised the efficacy of single-agent pembrolizumab compared with a platinum chemotherapy doublet (median overall survival 30 versus 14 months) in previously untreated NSCLC patients with a TPS for PD-L1 expression of 50%, and no EGFR or ALK gene alterations [64, 99] (ESMO MCBS 4). As a consequence pembrolizumab is now considered a standard treatment option in patients with advanced/mNSCLC and TPS for PD-L1 expression of 50%, who do not have contraindications to immunotherapy [1, A] . The KEYNOTE-042 trial including Asian patients [65] investigated pembrolizumab in patients with a TPS for PD-L1 of 1% disease and showed the overall survival benefit observed for pembrolizumab to be driven by patients with a TPS for PD-L1 expression of 50%. This provides confirmation of the fact that the benefit of single-agent pembrolizumab in the first-line setting reported in the KEYNOTE-024 trial, is restricted to patients with high tumour PD-L1 expression (TPS 50%).
Also, the KEYNOTE-189 trial in PS 0-1 patients, without sensitising EGFR or ALK mutations, showed the addition of pembrolizumab to pemetrexed and platinum-based chemotherapy (four cycles followed by pembrolizumab þ pemetrexed maintenance) to result in a superior response rate, median progressionfree survival (PFS) and estimated overall survival compared with pemetrexed and chemotherapy plus placebo [median overall survival (mOS) not reached versus 11.3 months, hazard ratio (HR) 0.49, 95% CI 0.38-0.64] [100]. In the KEYNOTE-407 trial in patients with metastatic squamous NSCLC, patients were randomised 1 : 1 to receive carboplatin and paclitaxel (or nab-paclitaxel) plus either pembrolizumab or placebo for four cycles, followed by pembrolizumab or placebo. Chemotherapy in combination with pembrolizumab was associated with an improved ORR and an improved overall survival (5.9 versus 11.3 months, P ¼ 0.0008) [101] . Based on these results, pembrolizumab in combination with platinum-based chemotherapy or pemetrexed and platinum-based chemotherapy should be considered as a (Figures 1 and  2) .
In IMpower 150, the only published trial at the time of the special guidelines meeting in Guangzhou to report data on patients with NSCLC with EGFR or ALK gene changes, the addition of atezolizumab to bevacizumab plus chemotherapy (four or six cycles followed by atezolizumab or atezolizumab þ bevacizumab or bevacizumab maintenance) in patients with non-squamous mNSCLC with a wild-type genotype (i.e. excluding patients with EGFR or ALK mutations) significantly improved PFS and overall survival (mOS 19.2 versus 14.7 months, HR 0.78, 95% CI 0.64-0.96, P ¼ 0.02) irrespective of tumour PD-L1 expression [102] . PFS was also longer for patients receiving atezolizumab, bevacizumab and chemotherapy than for those receiving bevacizumab and chemotherapy in the ITT patient population which included patients with NSCLC with EGFR or ALK mutations. These results support the use of a combination of atezolizumab (anti-PD-L1) and bevacizumab [antivascular endothelial growth factor (VEGF)] with carboplatin and paclitaxel as a therapeutic option in patients with non-squamous mNSCLC, and a PS of 0-1, in the absence of contraindications to the use of immunotherapy [I, A].
The addition of atezolizumab to platinum and taxane chemotherapy combinations (four or six cycles followed by atezolizumab) has also been studied in patients with squamous mNSCLC in the IMpower 131 study, but no improvement in overall survival was seen at first interim analysis (mOS 14.0 versus 13.9 months, HR 0.96, 95% CI 0.76-1.18) [103] . More mature data are needed to evaluate the long-term benefit but atezolizumab with carboplatin/nab-paclitaxel represents a potential option for patients with squamous mNSCLC [I; B].
The combination of carboplatin or cisplatin with pemetrexed and atezolizumab (four or six cycles followed by atezolizumab þ pemetrexed) in the IMpower132 trial has been shown to be superior to the chemotherapy doublet although overall survival was not statistically different at the time of analysis (mOS 18.1 versus 13.6 months, HR: 0.81, 95% CI: 0.64-1.03) suggesting another possible treatment opportunity [I, B] [104] . The combination of carboplatin nab-paclitaxel and atezolizumab (four or six cycles followed by atezolizumab) in the IMpower130 trial has been shown to be superior to the chemotherapy doublet, with an improvement of PFS and overall survival (mOS 18.6 versus 13.9 months; HR: 0.79; 95% CI: 0.64-0.98) suggesting an additional treatment opportunity [I, A) [105] . No benefit for the addition of atezolizumab to chemotherapy was observed in patients with EGFR/ALK gene alterations [105] . Atezolizumab is not approved by the European Medicines Agency (EMA) for use in the first-line treatment of NSCLC, but has been approved in certain Asian countries. In the KEYNOTE-189/407 trials as well as the IMpower 130/131/132 trials, the magnitude of the benefit was related to tumour PD-L1 expression.
As mentioned previously 'recommendation 2', a pre-specified analysis of TMB as a biomarker was reported in the phase III CheckMate 227 trial, evaluating the ICT mAbs nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) versus chemotherapy first-line in patients with stage IV or recurrent NSCLC that had not been previously treated with chemotherapy [76] . Patients with tumour PD-L1 expression of 1% and those with PD-L1 expression <1% were randomly assigned, in a 1 : 1 : 1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy or chemotherapy. The PFS benefit seen with nivolumab plus ipilimumab was irrespective of tumour PD-L1 expression with the HRs for nivolumab plus ipilimumab in patients with a tumour PD-L1 TPS 1% and those <1% of 0.62 and 0.48, respectively. A similar benefit was seen for patients with either squamous or non-squamous histologies (squamous HR 0.63, non-squamous HR 0.55). For now, nivolumab plus ipilimumab represents an option for the treatment of patients with NSCLC with a high TMB [I, A]. Ipilumumab and its combination with nivolumab are not currently approved by the EMA for use in the treatment of patients with NSCLC.
The impact of the TMB on the benefit of nivolumab was also examined in the CheckMate-026 trial in a retrospective unplanned analysis and showed patients with the highest TMB to benefit from nivolumab in terms of response and PFS [77] . Overall, the data from the trials cited above suggest that immunotherapy is emerging as a new treatment approach for most patients with newly diagnosed mNSCLC. However, the Asian experts were uncertain about the benefit conferred by the addition of pembrolizumab to chemotherapy in patients with high tumour cell PD-L1 (50%) given that there is no randomised trial that compares chemotherapy plus checkpoint inhibitors versus pembrolizumab monotherapy, and voted to accept 'recommendation 5c' above with some reservation [A ¼ 17% and
First-line treatment in NSCLC patients with no druggable oncogene driver but with contradictions for the use of immunotherapy. Platinum doublet chemotherapy should be considered for all stage IV lung cancer patients PS 0-2 without a druggable oncogene driver and without major comorbidities, 'recommendation 5g' above' [1, A] . This recommendation is based on the benefits demonstrated for chemotherapy over best supportive care (BSC) [106] [107] [108] and by the survival benefit demonstrated for the use of chemotherapy doublets over singleagent therapy [109, 110] . No overall survival benefit was found for the use of six versus fewer cycles of first-line platinum-based doublets, although a longer PFS coupled with significantly higher toxicity was reported in patients receiving six cycles [111, 112] . Thus, four cycles of platinum-based doublets followed by less toxic maintenance monotherapy [I, A], or four cycles of platinum-based therapy in patients not suitable for maintenance monotherapy [I, A], up to a maximum of six [IV, B], are currently recommended. Several platinum-based combinations with paclitaxel, docetaxel, gemcitabine and vinorelbine have shown comparable efficacy [113, 114] .
Selection of the appropriate regimen for the treatment of a particular patient should involve consideration of the balance between the efficacy and the toxicity profiles of the individual regimens. For example, cisplatin was shown to achieve higher response rates than carboplatin in a retrospective Cochrane review [115] , but trials using paclitaxel or gemcitabine plus a platinum agent had equivalent response rates. However, cisplatin was associated with more nausea or vomiting and carboplatin caused more thrombocytopaenia and neurotoxicity, whilst no difference in the incidence of grade 3/4 anaemia, neutropenia, alopecia or renal toxicity was observed [115] . Also, the incorporation of pemetrexed (a novel multi-targeted antifolate that inhibits three enzymes involved in folate metabolism and purine and pyrimidine synthesis) represents a therapeutic option based on data from the comparison of pemetrexed cisplatin with gemcitabine or docetaxel platinum combinations [116, 117] that should be restricted to use in non-squamous NSCLC patients only [118, 119] . Whilst, the albumin-bound nab-paclitaxel/carboplatin regimen has been shown in a large phase III trial to have a significantly higher overall response rate (ORR) compared with the solvent-based paclitaxel/carboplatin and less neurotoxicity, but no significant difference in PFS or overall survival [I, B] [120] . The nab-paclitaxel/carboplatin regimen could therefore be considered a therapeutic option in patients with advanced NSCLC, particularly in those patients with a greater risk of neurotoxicity, pre-existing hypersensitivity to paclitaxel or contraindications for standard paclitaxel premedication [I, B]. The benefits were observed in both SCC and NSCC, with a larger impact on response in patients with SCC [120] .
In fact, most individual trials and meta-analyses evaluating the chemotherapy options for the first-line treatment of patients with advanced/mNSCLC did not report any differential efficacy between patients with NSCC and SCC histologies [107] . Therefore, platinum-based doublets involving a third-generation cytotoxic agent (gemcitabine, vinorelbine, taxane) are recommended for both NSCC and SCC NSCLC patients without major comorbidities and PS 0-2 [I, A] (Figures 1 and 2) . However, there are some treatment strategies that are specific for the treatment of either NSCC or SCC. For example, necitumumab, a monoclonal antibody against EGFR, which failed to demonstrate a significant impact in the first-line treatment of metastatic NSCC when added to cisplatin/pemetrexed [121] , showed significant benefits when combined with cisplatin/gemcitabine in patients with SCC in the SQUIRE trial [122, 123] (ESMO MCBS score 1). However, a benefit from the addition of necitumumab to chemotherapy was not apparent for the small subgroup of patients with non-EGFR-expressing tumours. Thus, based on these results, and due to the limited clinical data, the addition of necitumumab to cisplatin and gemcitabine is an option for patients with EGFRexpressing SCC only. It should be noted that it has not been adopted as a standard treatment option in Europe and most Asian countries, and its use in NSCLC patients with SCC should be carefully evaluated [I, C; ESMO-MCBS score: 1]. Also, the combination of bevacizumab (anti-VEGF) with carboplatin and paclitaxel has been shown to improve survival in both Western and Asian patients with NSCC PS 0-1 NSCLC [124, 125] (ESMO MCBS score 2). Two meta-analyses also confirmed the superiority of bevacizumab platinum chemotherapy combinations over platinum combination therapy alone in NSCLC patients with NSCC [126, 127] . However, at the face-to-face meeting there was no consensus that bevacizumab could be used outside of combination with carboplatin and paclitaxel and therefore the Asian experts only accepted 'recommendation 5n' above with major reservation [A ¼ 17% and C ¼ 83%%].
Recommendation 6: maintenance 6a. Maintenance chemotherapy should be offered only to patients with PS 0-1 after first-line chemotherapy. Decisions about maintenance should consider histology, response to platinum-doublet chemotherapy and remaining toxicity after first-line chemotherapy, PS and patient's pref- supplementary Table  S4 , available at Annals of Oncology online). The Japanese experts only accepted 'recommendation 6a' with major reservation.
As stated in the ESMO guidelines [24] , decisions regarding maintenance therapy must take into account histology, residual toxicity after first-line chemotherapy, response to platinum doublets, PS and patient preference. 'Recommendations 6a, b, c and d' above are based on the data from several trials that have investigated the role of maintenance treatment in patients with good PS (0-1) either as 'continuation maintenance' (maintained use of an agent included in first-line treatment) or as 'switch maintenance' (introduction of a new agent) after four cycles of platinumbased chemotherapy. Randomised phase III trials of switch maintenance have reported improvements in PFS and overall survival for pemetrexed [118] and erlotinib [128] versus placebo, following four cycles of platinum-based therapy. This was confirmed for erlotinib in Asian patients from Korea, China and Malaysia, in a retrospective sub-group analysis of Asian patients enrolled in the SATURN trial both for the overall Asian patient population and for patients with EGFR IHC positive disease [129] . In the case of pemetrexed, the benefit was limited to those patients with NSCC. Furthermore, maintenance treatment with erlotinib is only recommended for NSCC patients with EGFR-sensitising mutations [III, B] [130] . Randomised trials investigating continuation maintenance have also shown an improvement in PFS and overall survival. The phase III PARAMOUNT trial of continuation maintenance with pemetrexed versus placebo after four induction cycles of cisplatin plus pemetrexed chemotherapy demonstrated a PFS and overall survival improvement in patients with a PS 0-1, which was confirmed at long-term follow-up [131, 132] . Continuation of pemetrexed following completion of four cycles of first-line cisplatin plus pemetrexed chemotherapy is, therefore, recommended in patients with NSCC, in the absence of progression after first-line chemotherapy and upon recovery from the toxicities of the previous treatment [I, A]. A phase III trial comparing maintenance bevacizumab, with or without pemetrexed, after first-line induction with bevacizumab, cisplatin and pemetrexed showed a benefit in PFS for the pemetrexedbevacizumab combination but no improvement in overall survival [133] . Although, a trend towards improved overall survival was seen when analysing 58% of events for the 253 patients randomised in this trial [134] . In the PointBreak trial, which compared carboplatin plus paclitaxel plus bevacizumab followed by bevacizumab to carboplatin plus pemetrexed plus bevacizumab followed by pemetrexed plus bevacizumab in patients with NSCC, overall survival was comparable for both arms (HR, 1.00; 95% CI: 0.86-1.16; P ¼ 0.949) [135] . Another phase III trial, showed that continuation maintenance with gemcitabine significantly reduced disease progression with a non-significant improvement in overall survival in patients with advanced NSCLC treated with four cycles of cisplatin/gemcitabine combination therapy first-line [ Table S5 , available at Annals of Oncology online, and subsequently recommendation 7d after face-to-face discussion resolved the issues surrounding current practice in one Asian country.
These recommendations are based on the fact that chemotherapy has been shown to prolong survival and improve quality of life (QoL) in NSCLC patients with PS 2 when compared with BSC [I, A] [137, 138] . Furthermore, a recent meta-analysis of randomised trials comparing the efficacy and safety of platinumbased doublets versus single-agent regimens in the first-line therapy of PS 2 patients has shown platinum-based regimens to be superior in terms of response rate and survival despite an increase in toxicities (mainly haematological) [139] . Whilst, the superiority of carboplatin-based combinations over monotherapy in PS 2 patients has been demonstrated in two large phase III trials [138, 140] , with an acceptable toxicity profile. Therefore, platinumbased (preferably carboplatin) doublets should be considered in eligible PS 2 patients [I, A]. Treatment with single-agent gemcitabine, vinorelbine, docetaxel [I, B], or pemetrexed (restricted to NSCC) [II, B] is an alternative option [140, 141] .
To date, all the phase III studies involving immunotherapies that have reported data, have excluded patients with a PS 2. However, preliminary data from the CheckMate 153 trial involving 108 patients with advanced NSCLC and a PS of 2 treated with single-agent nivolumab reported improved treatment outcomes for non-squamous NSCLC patients [142] . In addition a European-based phase II safety trial (CheckMate 171), also involving patients treated with nivolumab, of whom 98/809 had a PS of 2, has shown the safety for the patients with a PS of 2 to be comparable to that of the overall population [143] . Currently, the available data are insufficient to provide recommendations for the use of immune checkpoint inhibitors in PS 2 patients. Patients with a poor PS (3-4) should be offered BSC in the absence of known EGFR mutations, ALK or ROS1 rearrangements or a BRAF V600 mutation [III, B]. All 12 Asian experts agreed with and accepted completely [A ¼ 100%] 'recommendations 8a, b, and c', in the pre-meeting surveys. This was based on historical data from phase III trials in European and Asian patients that established single-agent chemotherapy (docetaxel, vinorelbine or gemcitabine) as the standard of care first-line in patients with mNSCLC aged 70 years [141, 144] , and from a more recent systematic review of randomised controlled trials that compared non-platinum single-agent therapy versus non-platinum combination therapy, or non-platinum therapy versus platinum combination therapy in patients >70 years of age with advanced NSCLC and showed platinum-based combination chemotherapy to be the preferred option for patients with a PS of 0-2 and adequate organ function [145] . However, platinumbased combination therapy is associated with an increase in treatment-related toxicities and its use needs to be balanced against the expected survival benefit. Concerns over treatment-related toxicity in elderly patients has led to the study of the use of the Comprehensive Geriatric Assessment (CGA) as a selection tool for treatment, based on a patient's fitness or frailty [146] . However, a multicentre, open-label, phase III trial, in elderly patients 70 years old with a PS of 0-2 and stage IV NSCLC randomly assigned between chemotherapy, on the basis of PS and age (standard arm: carboplatin-based doublet if PS 1 and age 75 years; docetaxel if PS ¼2 or age >75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and BSC for frail patients), showed treatment allocation on the basis of CGA to fail to improve treatment failure-free survival and overall survival, but to slightly reduce treatment-related toxicity [147] . Thus, a carboplatin-based doublet is the recommended treatment approach for elderly patients with a PS of 0-2 and adequate organ function [I, A], and for those patients not eligible for treatment with doublet chemotherapy, single-agent chemotherapy remains the standard of care [I, B] .
Also, although to date, no studies dedicated to elderly patients have been reported, evidence is accumulating for the use of ICT mAbs in the treatment of elderly patients with advanced NSCLC, supported by subgroup analyses from randomised second-line trials in patients with NSCLC aged 65 years and >65 years showing equivalent efficacy [148] [149] [150] [151] and no difference in toxicity [152] . Whilst, in a subgroup analysis of the KEYNOTE-024 trial there was no difference in the beneficial effect of pembrolizumab between patients aged 65 years and those aged >65 years of age (HR 0.61 versus 0.45) [64] . Similarly, in the CheckMate 026 trial, there was no difference in survival outcomes between patients treated with nivolumab aged 65 years when compared with >65 years [77] . Immunotherapy should therefore be considered for the treatment of elderly patients with mNSCLC. [III, A].
Recommendation 9: second-line treatment of patients with mNSCLC without a druggable oncogene driver Table S6 , available at Annals of Oncology online) and subsequently after discussion 'recommendations 9d and e', and the addition of the word inhibitor to 'recommendation 9e' see bold text above. Voting for 'recommendation 9h' was subsequently slightly changed with a vote of accepted with some reservation from one country (supplementary Table S13 , available at Annals of Oncology online). The acceptance of these recommendations was based on the fact that currently three PD-1 or PD-L1 therapies (nivolumab, pembrolizumab and atezolizumab) are approved by the United States Food and Drug Administration (FDA) and the EMA for use in the second-line setting for the treatment of patients with NSCLC. Nivolumab and atezolizumab are approved or use in patients with advanced NSCLC irrespective of PD-L1 expression, while pembrolizumab is approved only in patients with PD-L1 expression 1%. Approval of nivolumab was based on the data from two phase III studies, CheckMate 017 [149] and CheckMate 057 [148] (ESMO MCBS score 5). In the CheckMate 017 trial, 272 patients with squamous NSCLC were randomised to receive either nivolumab or docetaxel, and overall survival was shown to be significantly better for those patients who received nivolumab (HR 0.59, 95% CI: 0.44-0.49, P < 0.001). In the CheckMate 057 trial, 582 patients with non-squamous NSCLC were randomised to receive either nivolumab or docetaxel and again overall survival was significantly better for those patients who received nivolumab (HR 0.73, 95% CI: 0.59-0.89, P ¼ 0.002). Furthermore, a recent update of these studies has shown the 2-year overall survival results to favour nivolumab in both squamous (29% versus 16% with docetaxel) [I, A] and non-squamous NSCLC (23% versus 8% with docetaxel) [I, A]. Tolerability also favoured nivolumab, with 10% of patients experiencing grade 3-4 treatment-related adverse events (AEs) compared with 55% of patients receiving docetaxel.
Approval of pembrolizumab was based on the results of the KEYNOTE-010 trial which randomised 1034 patients with previously treated NSCLC and PD-L1 expression on at least 1% of tumour cells to receive either pembrolizumab or docetaxel [150, 153] . Overall survival was significantly longer for those patients receiving pembrolizumab (either 2 or 10 mg/kg) than for those receiving docetaxel (2 mg/kg, HR 0.72, 95% CI: 0.6-0.86; P < 0.001; 10 mg/kg, HR 0.60, 95% CI 0.49-0.72; P < 0.001), with a recently reported 2-year overall survival rates of 14.5% (2 mg/kg) versus 30.1% (10 mg/kg) [I, A]. Grade 3-5 treatmentrelated AEs were less common with pembrolizumab than with docetaxel (13%-16% versus 35%). There was no significant difference in the safety of pembrolizumab at doses of 2 or 10 mg/kg. Whilst, in the case of atezolizumab, the OAK trial, which evaluated 850 patients with advanced NSCLC previously treated with one or two prior lines of chemotherapy, randomised to receive either atezolizumab or docetaxel, showed atezolizumab to significantly improve overall survival (HR 0.73, 95% CI 0.62-0.87, P < 0.001) [151] . Tolerability was also better with atezolizumab, with 15% of patients experiencing a grade 3-4 treatment-related toxicity compared with 43% of those treated with docetaxel [I, A]. Thus, based on these trial data anti-PD-1/PD-L1 agents should be the treatment of choice for most patients with advanced, previously treated, PD-L1 inhibitor-naive NSCLC, irrespective of PD-L1 expression [I, A].
Historically, combination chemotherapy regimens have failed to show any benefit over single-agent treatments in terms of overall survival, second-line [154] . However, single agents do improve disease-related symptoms and overall survival compared with BSC [154] . Docetaxel has shown improved efficacy compared with BSC in randomised trials [155, 156] with similar efficacy, but more favourable tolerability for the weekly schedule compared with the 3-weekly to weekly schedules of docetaxel [I, B] [157, 158] . Pemetrexed demonstrated comparable efficacy to docetaxel in a randomised phase III trial but with a more favourable toxicity profile [159] . Whilst, a retrospective analysis demonstrated the differential effect of histology with an improvement in the efficacy (overall survival) of pemetrexed compared with docetaxel seen in patients with non-squamous NSCLC (9.0 versus 8.3 months; HR 0.78; 95% CI 0.61-1.0; P ¼ 0.004) [119] . Thus both docetaxel and pemetrexed (for NSCC only) represent confirmed second-line chemotherapy options, with comparable efficacy [I, B]. Second-line treatment duration should be individualised and prolongation of treatment is an option if disease is controlled and toxicity acceptable [24] .
Chemotherapy combined with antiangiogenic agents has been investigated in patients with pretreated advanced NSCLC. Ramucirumab, an VEGF receptor 2 (VEGFR2) antibody, in combination with docetaxel, achieved superior PFS and overall survival when compared with docetaxel and placebo even in patients, who did not show any response to first-line chemotherapy, and regardless of tumour histology [160, 161] (ESMO MCBS score 1). Combination of the oral angiokinase inhibitor nintedanib with docetaxel, improved PFS compared with chemotherapy alone in the LUME-1 trial with a significant prolongation of overall survival observed in the group of patients with adenocarcinomas (median overall survival 12.6 versus 10.3 months; HR 0.82, 95% CI 0.7-0.99; P ¼ 0.0359) [162] . Gastrointestinal events and transient elevation of liver enzymes were the AEs most frequently associated with nintedanib and again improved efficacy was seen in the poor prognosis patients with non-responding or rapidly progressing tumours [162, 163] . Combination of paclitaxel and bevacizumab is another treatment option based on the results of the ULTIMATE trial, which showed a prolongation of PFS for the combination of weekly paclitaxel and bi-weekly bevacizumab compared with docetaxel [164] .
However, there was considerable discussion amongst the Asian experts regarding 'recommendation 9j' that proposes that erlotinib (an EGFR TKI) represents a potential second-/third-line treatment option, particularly for patients with either EGFR wild-type tumours or tumours of unknown EGFR mutation status not suitable for immunotherapy or second-line chemotherapy. The experts could only agree to reject with some reservation or completely 'recommendation 9j' [D ¼ 66% and E ¼ 34%%], based on the growing number of reports of the inferiority of EGFR TKIs, compared with chemotherapy, in the treatment of pre-treated patients with EGFR wild-type tumours [165] . In a meta-analysis summarising the results of six randomised trials in 900 patients, the PFS for EGFR TKIs was significantly inferior to that for chemotherapy in patients with EGFR wild-type tumours (HR 1.37, 95% CI 1.20-1.56; P < 0.00001). However, these results did not translate into an OS difference (HR 1.02, 95% CI 0.87-12; P ¼ 0.81) in a Chinese trial in patients with advanced EGFR wild-type NSCLC [166] . A European analysis has reported a significant improvement in PFS and overall survival for patients receiving second-line chemotherapy compared with second-line EGFR TKI therapy in patients (n ¼ 1278) with pretreated NSCLC (PFS 4.3 versus 2.83 months, HR 0.66, 95% CI 0.57-0.77, OS 8.39 versus 4.99 months, HR 0.7, 95% CI 0.59-0.83; P < 0.0001) [167] .
In patients with advanced SCC, afatinib has been shown to be superior to erlotinib in the LUX-Lung 8 trial, in terms of both PFS and overall survival (PFS 2.4 versus 1.9 months, HR 0.82, 95% CI 0.68-1.00; P ¼ 0.041; OS 7.9 versus 6.8 months, HR 0.81, 95% CI 0.69-0.95; P ¼ 0.0077) [168] (ESMO MCBS score 2). However, the Asian experts could only agree to accept with major reservation [C ¼ 100%] 'recommendation 9k' that afatinib could be a therapeutic option in patients with advanced SCC [Eastern Cooperative Oncology Group (ECOG) PS 0-2] progressing on or after platinum-based chemotherapy, based on these data [I, C].
Thus, according to the ESMO 2018 Clinical Practice Guidelines for diagnosis, treatment and follow-up for mNSCLC [24] , patients clinically or radiologically progressing after firstline therapy, should be offered second-line therapy irrespective of whether they have received maintenance treatment [I, A]. So far, no prospective trials have determined the best second-line therapy following failure of first-line treatment with pembrolizumab, but the preferred recommendation would be platinum-based chemotherapy according to the first-line trial results [64] , as discussed above. Table S7 , available at Annals of Oncology online) and subsequently after discussion recommendation 10c, based on the data presented at the end of this section. This acceptance of the ESMO recommendations was made based on the recognition that EGFR mutation status is a longestablished [169, 170] predictive marker for the treatment of patients with NSCLC, as demonstrated by the results of phase III trials comparing first-(erlotinib and gefitinib) (ESMO MCBS score 4 for gefitinib and for erlotinib) and second-(afatinib) generation EGFR TKIs with standard platinum-based chemotherapy regimens (ESMO MCBS score 4) [171] [172] [173] [174] [175] [176] . The benefit on PFS conferred by EGFR-TKI therapy was consistent across all the above studies and was independent of gender, age, smoking status and PS. The benefit on PFS conferred by EGFR TKI therapy was also observed in patients of Asian ethnicity [171, 175] . Notably none of the above studies demonstrated any benefit for EGFR TKI therapy over platinum-based therapy in terms of overall survival, probably due to the high level of treatment crossover. However, these data support the use of EGFR TKIs as the standard-of-care first-line in the treatment of Asian patients with EGFR-mutated NSCLC [I, A] (Figure 3 ). Asian patients with PS 3-4 may also be offered an EGFR TKI therapy as they are likely to receive a similar clinical benefit [II, A] [177] , whilst Asian patients who have benefited from EGFR TKI therapy may continue to receive the same therapy beyond initial radiological progression as long as they are clinically stable [II, A] [178] [179] [180] . However, in the randomised, phase III, multicentre IMPRESS trial, conducted in 11 countries in Europe and the Asia-Pacific region, continuation of gefitinib plus chemotherapy after radiological disease progression on first-line gefitinib did not prolong PFS in patients receiving platinum-based doublet chemotherapy as subsequent-line therapy and platinum-based doublet chemotherapy remains the standard of care in this setting [181] .
In terms of the choice of EGFR TKI (Figure 3) , the randomised phase IIB Lux-Lung 7 trial, showed afatinib to significantly improve PFS and time to treatment failure in treatment-naive patients with EGFR-mutated NSCLC compared with gefitinib, with a manageable toxicity profile [182] . There was no significant benefit in overall survival [183] . The international, randomised, open-label, phase III ARCHER 1050 trial, randomly assigned patients with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or L858R) to receive dacomitinib or gefitinib until disease progression. Dacomitinib significantly improved PFS and overall survival compared with gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC [184, 185] (FDA but not EMA approved and not yet approved in Asia). According to the ESMO guidelines erlotinib, gefitinib and afatinib are recommended as first-line therapy in patients with advanced NSCLC who have active sensitising EGFR mutations, regardless of their PS [I, A] (with no preference for any of the three agents over the others) [I, A]. However, both afatinib and dacomitinib are associated with a higher incidence of grade 3 skin and gastrointestinal toxicity, and a significant proportion of patients receiving these agents require a dose reduction. Osimertinib, a third generation EGFR TKI that targets both sensitising EGFR mutations and the resistant exon 20 T790M mutation [58] , was compared with standard firstgeneration EGFR TKIs (gefitinib or erlotinib) in the phase III FLAURA trial [186] . Osimertinib showed a significant improvement in PFS compared with that of the standard EGFR-TKIs (PFS 18.9 versus 10.2 months; HR 0.46, 95% CI 0.37-0.57; P < 0.0001) in the first-line treatment of EGFR mutationpositive advanced NSCLC, with a similar safety profile and lower rates of serious AEs. Osimertinib can be considered one of the options for patients with sensitising EGFR mutation positive NSCLC ( Figure 3 and Table 5 ).
A Japanese trial was the first to investigate EGFR-TKI therapy in combination with the antiangiogenic agent bevacizumab, versus erlotinib alone and demonstrated a significant difference in PFS (16.4 and 9.8 months, HR 0.52, 95% CI 0.35-0.76) [187] . Meanwhile comparison of bevacizumab plus erlotinib to erlotinib in the Japanese phase III NEJ026 first-line trial reports encouraging interim results with a significant benefit in terms of PFS for the combination therapy over elotinib alone (PFS 16.9 versus 13.3 months, HR 0.60, 95% CI 0.41-0.87), and updated Whilst, the Japanese NEJ009 trial is the first phase III study to evaluate the efficacy of combination therapy with an EGFR-TKI (gefitinib) and a platinum doublet (carboplatin/pemetrexed) in untreated patients with advanced NSCLC with EGFR mutations [190] . Carboplatin/pemetrexed/gefitinib combination therapy demonstrated a significantly better PFS (20.9 versus 11.2 months, HR: 0.49, 95% CI 0.39-0.62) and overall survival (52.2 versus 38.8 months, HR: 0.69, 95% CI 0.52-0.92) when compared with gefitinib alone, as first-line therapy, but is not currently approved. 
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11f. Platinum-based doublet is the standard therapy for patients whose tumour is tested T790M negative in either re-biopsy or in liquid biopsy (only when re-biopsy is not feasible) [A ¼ 100% and I, A]. 11g. Combination of atezolizumab and bevacizumab with carboplatin and paclitaxel might be considered as a therapeutic option in patients with EGFR-mutated tumours, PS 0-1, in absence of contraindications to use of immunotherapy after targeted therapies has been exploited [A ¼ 100% and IV, C, after discussion].
All 12 Asian experts agreed with and accepted completely [A ¼ 100%] 'recommendations 11a, b, c, d and f' in the premeeting survey (supplementary Table S8 , available at Annals of Oncology online) and subsequently after discussion 'recommendations 11e and g'. In the case of 'recommendation 11e' the word highly was removed from the statement 'osimertinib is highly active'. In the case of 'recommendation 11g' the level of evidence was revised to IV, C as there was no specific trial addressing this treatment approach second-line and should was changed to might (see bold text above).
Almost all patients who benefit from EGFR TKIs will develop clinical resistance and progress after 9-12 months of treatment. Various mechanisms of resistance to first-generation TKIs have been described [164] . The most common mechanism of resistance (49%-60% of cases) involves the acquisition of EGFR exon 20 T790M mutations [191] . However, a number of thirdgeneration EGFR TKIs are designed to specifically target the EGFR T790M mutation [23] . To date, the only approved treatment of mNSCLC patients with tumour EGFR T790M mutations is osimertinib, based on data from the randomised phase III AURA 3 trial, in 419 patients, that compared osimertinib with pemetrexed-platinum in patients with proven EGFR T790M mutations at the time of their progression on first-/second-generation EGFR-TKI therapies [53] (Figure 3) . The ORRs were 71% and 31%, for osimertinib and pemetrexed-platinum, respectively [odds ratio (OR) 5.39, 95% CI 3.46-8.48; P < 0.001]. The primary end point (PFS) was also significantly different (10.2 versus 4.4 months; HR 0.30, 95% CI 0.23-0.41; P < 0.0001). Also, among the 144 patients with metastases to the CNS, the median duration of PFS was longer among patients receiving osimertinib than among those receiving pemetrexed-platinum therapy (8.5 versus 4.2 months; HR 0.32; 95% CI 0.21-0.49). In addition, the proportion of patients with AEs of grade 3 or higher was lower in those patients receiving osimertinib (23%) than those receiving pemetrexed/platinum therapy (47%) [53] . This study indicates that all patients with clinical resistance to first-/second-generation EGFR TKIs should be tested for the presence of the EGFR T790M mutation, and that osimertinib should be offered as standard treatment of patients who have EGFR T790M mutationpositive disease [I, A] [24] (ESMO MCBS score of 4).
In patients with resistance to EGFR TKI therapy in the absence of a tumour EGFR T790M mutation, the mechanisms of resistance can include MET gene amplification, PIK3CA alterations, KRAS mutations and small cell transformation. Thus, as per the ESMO Guidelines [24] , the current recommended standard of care for these patients is a platinum-based doublet, based on the data from the IMPRESS trial [181] . Results of the IMpower 150 trial (see Recommendation 5, first-line treatment of NSCLC without a druggable oncogene driver) [102] , which included data on patients with EGFR or ALK genetic alterations, support the use of a combination of atezolizumab (anti-PD-L1) and bevacizumab with carboplatin and paclitaxel as a therapeutic option in patients with non-squamous mNSCLC, and a PS of 0-1, in the absence of contraindications to the use of immunotherapy and may be an option also in the second-line setting [IV, C] (Figure 3) . However, following the meeting in Guangzhou, two publications [192, 193] reported a lack of efficacy for ICT mAbs as single-agents second-line, in TKI naive, PD-L1þ, EGFRmutant patients with advanced NSCLC, including those with PD-L1 expression 50%. These data suggest that these agents may not be an appropriate therapeutic choice in this setting. The antitumour activity of the dual ALK and MET TKI crizotinib was initially demonstrated in two multicentre, single-arm studies, in NSCLC patients harbouring an ALK rearrangement [194, 195] . Subsequently, the phase III PROFILE 1014 and 1029 trials, comparing crizotinib with platinum-pemetrexed (without maintenance pemetrexed) as first-line treatment in ALK-rearranged advanced NSCLC, demonstrated a significantly longer PFSs and higher ORRs for patients treated with crizotinib than for those treated with chemotherapy [196, 197] . As a consequence, first-line treatment with crizotinib is a treatment option for patients with ALK-rearranged NSCLC [I, A] (EMA approved in first-line, ESMO MCBS score 4). The second-generation ALK inhibitors ceritinib and alectinib have also shown robust antitumour efficacy, along with intracranial activity, in patients with ALK-rearranged NSCLC in the ASCEND [198, 199] and J-ALEX [200] trials. Indeed the head-to-head Japanese phase III J-ALEX trial comparing alectinib with crizotinib, showed alectinib to be superior to crizotinib as an initial treatment with an HR for PFS of 0.34 (95% CI 0.17-0.70; P < 0.0001). A similar head-to-head global trial of alectinib and crizotinib (the ALEX trial) in ALKrearranged treatment-naïve patients also showed investigator assessed PFS to be significantly longer for alectinib than for crizotinib (PFS 34.8 versus 10.9 months; HR: 0.43, 95% CI 0.32-0.58) [201, 202] . In patients with baseline CNS metastases, PFS was 27.7 months for alectinib versus 7.4 months for crizotinib (HR 0.35, 95% CI 0.22-0.56) [201] . Also, grade 3-5 AEs were less frequent with alectinib (41% versus 50% with crizotinib). In a phase III trial (ALTA 1) in patients with ALK-positive mNSCLC who had not previously received an ALK inhibitor, superior efficacy against systemic and intracranial disease and a significantly longer PFS was observed for those patients who received the ALKinhibitor brigatinib than for those who received crizotinib [203] . Thus, front-line use of ALK TKIs is effective in patients with ALK-rearranged NSCLC including those with CNS involvement (Figure 4) , and additional text has been added to 'recommendation 12c above', and in Table 2 . The EMA has approved alectinib for use in first and later-lines and ceritinib in second-line in following crizotinib failure, for patients with ALK translocated NSCLC, and brigatinib has recently received favourable opinion for approval from the EMA for use second-line post crizotinib (see below). Table S9 , available at Annals of Oncology online) and subsequently after discussion 'recommendations 13d and f'. In the case of 'recommendation 13 f' the level of evidence was revised to V, C as there was no specific trial addressing this treatment approach second-line and the word should change to might (see bold text above) and supplementary Table S13 , available at Annals of Oncology online and Table 2 .
Crizotinib was shown to be superior to second-line chemotherapy (either pemetrexed or docetaxel) in TKI-naïve patients with previously treated ALK-rearranged NSCLC in the phase III PROFILE 1007 trial, in terms of ORR and PFS [204] . Whilst, ceritinib (ASCEND-5 trial) [205] and alectinib (ALUR trial) [206] have both been shown to significantly improve mPFS compared with chemotherapy (5.4 months, 95% CI 4.1-6.9 for ceritinib versus 1.6 months, 95% CI 1.4-2.8 for chemotherapy; HR 0.49, 95% CI 0.36-0.6; P < 0.0001 and 9.6 months, 95% CI 6.9-12.2 for alectinib versus 1.4 months, 95% CI 1.3-1.6 for chemotherapy (HR 0.15, 95% CI 0.08-0.29; P < 0.001) in patients with ALKpositive NSCLC previously treated with crizotinib and chemotherapy. These data, support the use of ceritinib and alectinib in patients with ALK-positive advanced NSCLC who progress on treatment with, or are intolerant to, crizotinib [I, A] (Figure 4) . Their use is also proposed in ALK-rearranged NSCLC patients progressing on crizotinib with CNS progression [I, A]. The nextgeneration ALK inhibitors, such as brigatinib or lorlatinib, target a wider range of ALK-resistance mutations, and sequential therapy with these ALK inhibitors is the preferred treatment approach in crizotinib-resistant and/or second-generation-resistant populations based on the results of the ALTA trial evaluating brigatinib in crizotinib-resistant ALK-rearranged NSCLC patients [207] , and a phase I study with lorlatinib in ALK-rearranged patients pretreated with one, two or more ALK TKIs, including patients with CNS metastases at baseline (intracranial ORR 42%) [208] . However, brigatinib has been shown to have limited clinical activity in alectinib-refractory ALK-positive mNSCLC [209] . Thus, studies are needed to establish biomarkers of response to brigatinib and to identify effective therapeutic options for alectinib-resistant ALK-positive NSCLC patients. A phase II study of brigatinib after first-line ceritinib or alectinib [NCT03535740], is ongoing. A phase II study of lorlatinib in patients with ALK-or ROS1-rearanged NSCLC at the recommended phase II dose has demonstrated a 69% response rate in crizotinib-pre-treated patients, and a 39% RR in patients who had received previous treatment with two or more ALK TKIs. In patients previously treated with one or more second-generation ALK TKIs, a higher proportion of patients harbouring a secondary ALK mutation responded to treatment with lorlatinib compared with those without detectable ALK mutations [210] . However, data suggest that the sequential use of ALK TKIs can encourage the emergence of other ALK mutations [211] . At the present time, brigatinib has received a favourable opinion for approval by the EMA for use in crizotinib-resistant, ALKþ patients, and the approval for lorlatinib is pending. As reported above, results of the IMpower 150 trial (which included patients with EGFR or ALK genetic alterations) [102] , support the use of a combination of atezolizumab (anti-PD-L1) and bevacizumab with carboplatin and paclitaxel as a therapeutic option first-line in patients with non-squamous mNSCLC and a PS of 0-1, in the absence of contraindications to the use of immunotherapy, and may be an option also in the second-line setting in patients with ALK-rearranged NSCLC [V, C]. This was based on data on 50 patients with ROS1-rearranged NSCLC included in the PROFILE 1001 trial [212] , which reported an ORR for crizotinib of 72%, a disease control rate of 90% and a median PFS of 19.2 months. A small prospective French phase II trial [213] and a retrospective subgroup analysis of the EUROS1 trial [214] of crizotinib for patients with ROS1-rearranged NSCLC, reported mPFSs of 10.0 and 9.1 months, and ORRs of 72% and 80%, respectively. In an Asian phase II study of crizotinib in 127 patients with ROS1-rearranged lung cancer, the mPFS was 13.4 months [215] . Thus, single-agent crizotinib is recommended in the first-line setting or second-line in patients with stage IV NSCLC with an ROS1 rearrangement [III, A]. In a Korean phase II study, 32 patients with ROS1-rearranged advanced NSCLC were treated with ceritinib [216] . Among crizotinib-naïve patients, the ORR was 67%, with a disease control rate of 87%. Ceritinib might be an option for crizotinib-naïve patients but is currently not approved by the EMA [III, C]. The BRAF V600E mutation is observed in 1%-2% of lung adenocarcinomas [217] [218] [219] , particularly in those patients with a history of smoking. The activity of the BRAF inhibitors vemurafenib, dabrafenib and sorafenib was confirmed in a European retrospective cohort study in patients with BRAF-mutant lung adenocarcinoma [220] . Overall survival with first-line therapy was 25.3 months for patients with V600E mutant disease and 11.8 months for patients with non-V600E mutant disease. Thirty-one patients received one BRAF inhibitor, and four received a second inhibitor. The ORR for patients receiving BRAF therapy was 53%, and the disease control rate was 85%. In a vemurafenib basket trial (VE-BASKET), a total of 19 NSCLC patients were assessable for response. Overall, one patient was treatment-naïve and 50% and 45% of patients had received one or two or more lines of therapy before inclusion in the study, respectively. The ORR, PFS and overall survival were 42%, 7.3 months and not yet reached, respectively [221] . A multicohort phase II study of dabrafenib monotherapy (cohort A), or combination therapy with a MEK inhibitor (trametinib) (cohort B, beyond first-line and cohort C in first-line treatment) in patients with BRAF V600E-mutant metastatic NSCLC reported an ORR of 33%, and a mPFS and median duration of response of 5.5 and 9.6 months, respectively, for patients receiving dabrafenib monotherapy [222] . In pretreated patients receiving the combination of dabrafenib and trametinib the ORR was 66% and mPFS and median duration of response (mDoR) were 10.2 and 9.8 months, respectively [223, 224] . In treatment-naïve patients receiving a combination of dabrafenib and trametinib therapy the ORR was 64% and mPFS and mDoR were 10.9 and 10.4 months, respectively [225] . As a consequence, the EMA and FDA have approved dabrafenib in combination with trametinib for the treatment of patients with BRAF V600-mutation-positive advanced or mNSCLC. BRAF/MEK inhibition using dabrafenib with trametinib is also recommended in patients with BRAF inhibitor-naïve, stage IV NSCLC with a BRAF V600E mutation [III, A] (Figure 4 All 12 Asian experts agreed with and accepted completely [A ¼ 100%] 'recommendations 17a-e', in the pre-meeting surveys. This was based on the well-established role of EBRT in the symptom control of metastases, such as painful chest wall disease, painful bone metastasis, superior vena cava syndrome, soft tissue or neural invasion [23] . Thirty to 40 percent of patients with NSCLC will develop bone metastases. A recent systematic review of palliative EBRT regimens for patients with thoracic symptoms from NSCLC includes data from 14 randomised controlled trials involving 3576 patients [226] . Also, as described previously, EBRT is also indicated in cases of haemoptysis, symptomatic airway obstruction and sometimes following surgery for CNS metastases and bone metastases [23] . The data on the optimal timing of thoracic RT and systemic therapy in patients with stage IV NSCLC are sparse. Furthermore, to date, there is no evidence that the concurrent administration of chemotherapy, targeted agents or immunotherapy with palliative RT is beneficial in this group of patients [24] .
EBB is another method that can be used for the palliation of thoracic symptoms. The effectiveness of EBB compared with EBRT or other alternative endoluminal treatments was assessed in a Cochrane systematic review [227] , which concluded that EBRT alone was more effective for palliation than EBB alone [ All 12 Asian experts agreed with and accepted completely [A ¼ 100%] 'recommendations 18b-h and j and k', in the premeeting surveys (see supplementary Table S10 , available at Annals of Oncology online) and 'recommendation 18a' after discussion at the face-to-face meeting. For 'recommendation 18i' the level of evidence was changed from IIB to IIC and the word should changed to can (see bold text above). Ultimately, the recommendation was accepted by five countries with some reservation [B ¼ 83%] and one country with major reservation [C ¼ 17%], due to the limited available data.
CNS metastases are frequently identified in patients with NSCLC, predominantly in patients with adenocarcinomas. Approximately 30%-64% of patients with mNSCLC have CNS metastases.
As described previously [23] , the treatment of patients with brain metastases and no driver mutations is based on prognosis estimated using the Radiation Therapy Oncology Group RPA [228] . Radiation therapy is not recommended for RPA class III patients (who have a Karnofsky index of 70%) based on their dismal prognosis (median survival is generally <2 months). The role of WBRT in unselected patients has been questioned by data following the results of phase III non-inferiority QUARTZ trial, in which patients were randomised to receive either BSC including dexamethasone plus WBRT (20 Gy in five daily fractions) or the same BSC without WBRT [229] which reported no difference between the treatment arms in terms of symptom relief, steroid use, overall survival, QoL or quality-adjusted life years, confirming no benefit for WBRT in the RPA class III subset [I, A]. A signal for WBRT benefit was seen for younger patients with better Karnofsky indices and either controlled primary or noextracranial disease. WBRT can therefore be considered for patients with prognostic factors for better survival such as driver mutations [III, C]. The most frequent WBRT schedules are 20 Gy in 5 fractions or 30 Gy in 10 fractions, with no difference in outcome [I, A] [230] . For most patients with symptomatic brain metastases and/or significant oedema, dexamethasone or equivalent corticosteroid is recommended [III, A] [231] . Tapering of the dose and, if possible, cessation after RT, are recommended. In patients with asymptomatic brain metastases corticosteroid use is not recommended. WBRT-induced tumour shrinkage has been shown to correlate with better survival and preservation of neurocognitive function (NCF) [232] . Also, tumour progression was shown to adversely affect NCF more than WBRT, identifying enhancement of radiation response as being important in these patients. Neuroprotective agents have not demonstrated a convincing role in this setting and are not recommended for routine use [II, C], although a small phase III trial of memantine (RTOG 0614) suggested a benefit [233] . Hippocampus avoidance WBRT is probably safe [234] , but is still undergoing trial evaluation and is not currently recommended [III, C].
In the case of patients with single brain metastases surgical resection can be considered [235] [236] [237] , and postoperative WBRT or SRS is generally recommended [I, A] [238] . SRS alone is a treatment strategy in the case of RPA class I and II patients with a limited number of metastases [III, B] [239] [240] [241] . In fact, SRS has increasingly become the favoured treatment modality due to the fact that it is less toxic than WBRT. However, there is no randomised trial comparing SRS alone with WBRT. A survival advantage in favour of WBRT plus SRS has been demonstrated when compared with WBRT, but only in patients with a single brain metastasis [254] . The majority of studies evaluating WBRT as an adjunct to SRS or neurosurgery have shown a decline in cognitive function in the combined arm [242, 243] . SRS alone with close follow-up, without WBRT consolidation, is therefore a recommended strategy [III, B] . SRS of the surgical cavity in patients who have had complete resection of one to three brain metastases has been shown to lower the incidence of local recurrence when compared with observation alone [24, 244] .
Although it is generally accepted that SRS should be considered for the treatment of patients with 4 brain metastases, a prospective observational study from Japan challenged this view [245] . The study enrolled 1194 eligible patients (76% had lung cancer) with one to ten newly diagnosed brain metastases, longest diameter <3 cm, largest tumour <10 ml in volume and a total cumulative volume of 15 ml, and showed the overall survival outcome to be the same for patients with 2-4 metastases and those with 5-10 metastases, treated with SRS. This study therefore suggested the use of tumour volume and absolute size rather than the number of metastases as treatment criteria. In most countries, SRS is now based on total tumour volume rather than numbers of metastases, as the risk of radionecrosis increases with tumour volume [III, C] [242] . In patients undergoing SRS, radionecrosis is a challenging complication to manage.
In patients with asymptomatic brain metastases who have not yet received prior systemic therapy (i.e. chemotherapy, TKIs), treatment with upfront systemic therapy and deferred RT should be considered, with trial data suggesting similar intracranial and extra-cranial ORRs [II, B] [246, 247] . In a phase III Asian trial in patients with EGFR-mutant NSCLC and multiple brain metastases, icotinib (an EGFR-TKI) was associated with significantly longer intracranial PFS than whole brain irradiation plus chemotherapy, indicating that EGFR TKIs might be a better firstline therapeutic option for this patient population [248] . In patients suitable for first-line ICT mAb therapy, CNS metastases are generally mandated to have been treated before therapy in most available clinical trials. Evidence of intracranial responses has been demonstrated in smaller series and across diseases, but evidence remains limited regarding the safety and efficacy of immunotherapy in patients with small volume, untreated, NSCLC CNS metastases [III, B] [249] .
Between 44% and 60% of mNSCLC patients with a druggable oncogene driver (e.g. EGFR, ALK), develop brain metastases during the course of their disease [250, 251] . For these patients, the evidence suggests that the use of CNS-penetrant next-generation TKIs (e.g. osimertinib, alectinib, ceritinib, brigatinib) may restore control of brain disease, thereby potentially delaying cranial RT [II, A] [186, 199, 202] . Also, next-generation TKIs may also reduce the incidence of new CNS metastases thereby significantly postponing the time to until patients need CNS RT [184] . (see supplementary Table S11 , available at Annals of Oncology online) and recommendations 19c after discussion at the face-to-face meeting, and based on the data presented below.
LMD is a deadly complication of solid tumours and is associated with a poor prognosis. Of the patients with NSCLC who present with CNS metastases (30%-64%), 4%-7% present with LMD [252] . The incidence and prevalence of LMD is increasing due to screening for brain metastases, better imaging modalities, as well as a prolongation of patient survival in those with CNS metastases.
Patients with LMD may present with non-specific neurological symptoms (headaches, nausea, vomiting) as well as discrete signs related to the CNS area involved (gait difficulties, cranial nerve palsies). Diagnosis may involve cerebrospinal MRI with contrast enhancement, ideally before cerebral spinal fluid (CSF) intervention. CSF sampling with cytological assessment, is diagnostic [IV, A].
The prognosis for patients with NSCLC LMD is poor, and the treatment aim is to prolong survival coupled with an acceptable QoL. Patients with druggable oncogenic drivers may derive benefit from a CNS-penetrant next-generation TKI as per those with brain metastases [III, B], as described previously for icotinib under 'recommendation 18' above [248] , and in a recent review [253] , Also, investigation of afatinib versus platinum-based chemotherapy first-line in EGFR-mutation-positive patients with NSCLC and brain metastases supported the clinical activity of afatinib in this setting [254] . The specific and strong CNS activity of osimertinib might also suggest its use in this context (IV, C) [53, 186] (see supplementary Table S12 , available at Annals of Oncology online) and 'recommendations 20e' after discussion at the face-to-face meeting and rewording of the recommendation to remove the wording 'considered as synchronous secondary primary tumours and if possible' after 'should be', and the addition of 'unless contraindicated' (see also bold text above) after 'therapy', based on the data presented below.
Long-term disease control, or even cure, can be achieved in some subgroups of patients with OMD after aggressive local treatment of distant metastases with surgery or high-dose RT [257] . However, almost all the published clinical trials investigating local treatment of OMD, in patients with NSCLC, have limited inclusion to patients with 5 metastases. In addition, the vast majority of the trials included patients with 3 metastases and in an individual patient meta-analysis, almost 90% of the patients had a single metastasis [257] . Some studies also limited the number of organs in which these metastases are present [258] .
Oligometastases can be either synchronous or metachronous [259] and their biology may differ, as suggested by the fact that patients with metachronous oligometastases have a better prognosis [257] . In patients receiving systemic therapy (mainly in tumours with driver mutations treated with TKIs), the term oligoprogression can be also applied in the case of the progression of a limited number of metastatic lesions, when all the other lesions remain stable.
The specific approach to the treatment of oligometastases in the brain has been discussed above ('recommendation 18'). However, another subgroup requiring discussion is that of patients with a solitary lesion in the contralateral lung. The International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee carried out a systematic literature review, aimed at distinguishing a second primary from a metastasis in patients who have more than one pulmonary nodule [86] . This review concluded that few features are definitive, with many commonly used factors being suggestive, carrying a substantial risk of misclassification as the majority of second primary lung tumours are of the same histology. For these cases, the IASLC recommended a careful review by a multidisciplinary tumour board, and pursuit of radical therapy, such as that for a synchronous secondary primary tumour, when possible. Both surgery [259, 260] and SRS [261, 262] have been shown to generate patients who are long-term survivors, in this setting [IV, B] .
A systematic literature review showed surgery to be the most common treatment approach for both the primary tumour (n ¼ 635, 83.9%) and metastases (n ¼ 339, 62.3%). Predictive factors for overall survival were synchronous versus metachronous metastases (P < 0.001), N-stage (P ¼ 0.002) and adenocarcinoma histology (P ¼ 0.036) [257] . Whilst, RPA for risk groups identified a good prognosis (low-risk) group presenting with metachronous metastases (5-year overall survival 48%), an intermediate-risk group presenting with synchronous metastases and N0 disease (5-year overall survival 36%) and, finally, a highrisk group presenting with synchronous metastases and intrathoracic N1/N2 disease (5-year overall survival 14%). However, it should be noted that the positive outcomes in these patients might not be due solely to treatment, but also to patient selection or other biases [263] .
Stage IV patients with limited synchronous metastases at diagnosis may experience long-term disease-free survival (DFS) following systemic therapy and local consolidated therapy (LCT) such as high-dose RT including stereotactic ablative body RT (SABR) or surgery [III, B] . Five phase II trials evaluating LCT in patients with NSCLC and synchronous oligometastases have been published. Three small, single-arm studies generally showed durable PFS in a subgroup of patients [264] [265] [266] , whilst two randomised phase II studies were stopped early after interim analysis. The first of these phase II studies randomised mNSCLC patients with 3 metastases, without progression after first-line systemic therapy (n¼49), between consolidative therapy [(chemo) RT or surgery] with or without maintenance or maintenance treatment alone and showed a significant difference in PFS time between the two groups [PFS 11.9 months in the LCT (surgery) group versus 3.9 months in the maintenance group; HR¼0.35, P ¼ 0.005] [267] . The second phase II study randomised patients with 5 metastatic sites between maintenance chemotherapy alone and SABR followed by maintenance chemotherapy (n ¼ 29) [268] . So far, there are no published data on the impact of LCT on overall survival and long-term toxicity. Stage IV NSCLC patients with limited metachronous metastases may be treated using radical local treatment such as high-dose Rt or surgery, as some patients may experience long-term DFS [IV, B] . However, this is based mainly on retrospective data. There is also a paucity of prospective data to support this treatment approach in patients with driver mutations who present with oligoprogression on molecular-targeted therapies [IV, C]. Furthermore, there are little data on the safety of combining SABR with molecularly targeted agents.
Some recommendations for the implementation of standardof-care, and advanced imaging modalities for identifying and following up patients with OMD, have been published by the European Organisation for Research and Treatment of Cancer (EORTC) imaging group [269] . In the synchronous, metachronous and oligoprogressive disease settings, inclusion of patients in clinical trials is preferred because of the limited evidence available. Bone metastases occur in 30%-40% of patients with NSCLC, and it may be reasonable to evaluate bone disease at diagnosis. In general, the treatment approach is to palliate symptoms and prevent complications. Palliative RT is highly effective and usually achieves rapid pain relief. Both standard EBRT and SABR can be used to palliate painful, uncomplicated bone pain. Systematic reviews of palliative RT trials of patients with bone metastases have shown single-and multiple-fraction regimens to provide equal pain relief. However, retreatment rates were significantly higher for those patients receiving single-fraction treatment [I, A] [270, 271] .
The bisphosphonate zoledronic acid has been shown to reduce skeletal-related events (SREs) (pathological fracture, radiation or surgery to bone, or spinal cord compression) in patients with NSCLC [II, B] [272, 291] . Denosumab, a monoclonal antibody that slows the breakdown of bone, has shown a trend towards superiority over zoledronic acid in advanced solid tumours in terms of SRE prevention [II, B] [273, 292] , and in a large phase III trial, denosumab was associated with improved overall survival in a subgroup of 702 patients with mNSCLC [274] . In a phase III trial of denosumab versus zoledronic acid in patients with advanced cancers (44% NSCLC), denosumab significantly delayed the time to first on-study SRE compared with zoledronic acid. Denosumab also reduced the time period over which pain interfered with daily life (used as surrogate for QoL) and worsening pain interference in patients with no/mild baseline pain [275] . Zoledronic acid or denosumab are thus recommended in selected patients (life expectancy >3 months at high risk of SREs) with advanced lung cancer with bone metastases [I, B]. Early palliative care intervention is recommended, in parallel with standard oncological care [I, A], with evidence demonstrating that palliative care interventions significantly improve QoL (ESMO MCBS score 4). Two randomised trials evaluating the impact of introducing specialised, early, palliative care after diagnosis of stage IV NSCLC on patient QoL in ambulatory patients were able to show improvements in QoL and mood [276] , and in one trial, a reduction in aggressive treatment and an improvement in overall survival [277] . Due to the aggressive nature of this disease, generally close follow-up, at least every 6-12 weeks after first-line therapy, is advised to allow for early initiation of second-line therapy but should also depend on individual retreatment options [III, B].
Conclusions
The results of the voting by the Asian experts both before and after the face-to-face meeting in Guangzhou showed high concordance (supplementary Table S1 -S13, available at Annals of Oncology online) with the ESMO recommendations for the treatment of patients with mNSCLC published as part of the 2016 'ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up' for mNSCLC [23] , and the July 2018 update of these guidelines [24] . In terms of level of agreement, there were no votes of less than an A (accept completely) following the faceto-face discussions, except for 'recommendations 3 l Table S13 , available at Annals of Oncology online).
Thus, these guidelines can be considered to be consensus guidelines for the treatment of patients with mNSCLC in Asia, with 80% of experts voting to accept completely or accept with reservation a specific recommendation except for 'recommendations 5n (overall vote C), 9j (overall vote D) and 9K (overall vote C). As mentioned previously, the levels of agreement provided by each of the Asian experts were based on the available 'scientific' evidence, and were independent of the approval and reimbursement status of certain drugs (including biologics) in their individual countries. A summary of the approval and reimbursement status of the recommended drugs, as of July 2018, is presented for each participating country in Table 5 and will obviously impact on some of the treatment strategies that can be adopted by certain countries.
